OncoCyte Corporation – Consensus Indicates Potential 34.5% Upside

Broker Ratings

OncoCyte Corporation with ticker code (OCX) now have 7 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 11 and 2 with a mean TP of 6.43. Now with the previous closing price of 4.78 this indicates there is a potential upside of 34.5%. There is a 50 day moving average of 5.27 and the 200 day moving average is 2.71. The market cap for the company is $421m. You can visit the company’s website by visiting: http://www.oncocyte.com

OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits
You might also enjoy reading  OncoCyte Corporation - Consensus Indicates Potential 127.8% Upside

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index